Pre-order Enquiry
Request Free Sample
Global Tinea Pedis Treatment Market Outlook 2022
SKU ID : QYR-19610504 | Publishing Date : 29-Nov-2021
Request Sample
Request Customization
Check Discounts
Tinea infections are fungal infections caused by T rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum. This dermatophyte fungus thrives in humid conditions. The clinical features of tinea pedis include patchy and dry scaling on foot and presence of blisters or pustules on feet and between toes.
The rising prevalence of diabetes that is fueling the incidence of tinea pedis is one of the primary growth factors for this market. There is an increased prevalence of diabetes across the globe due to high levels of sugar in the blood streams and this results in numerous health issues. Diabetes reduces the quality of life, increases the risk of obesity, and early death. People with diabetes tend to be more resistant to antifungal treatment regimens due to high blood glucose levels which increases the chances of fungal growth. Consequently, diabetes patients tend to have a high risk of foot ulcerations and infections that can lead to tinea pedis or onychomycosis resulting in the need for the effective treatment of this infection.
The global Tinea Pedis Treatment market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Tinea Pedis Treatment volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Tinea Pedis Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Tinea Pedis Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Interdigital
Vesicular
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
GSK
Exeltis USA
Valeant
Incyte
Celgene
Hisamitsu Pharmaceutical
NovaBiotics
Elorac
F. Hoffmann-La Roche
Sanofi
Teva Pharmaceutical
The rising prevalence of diabetes that is fueling the incidence of tinea pedis is one of the primary growth factors for this market. There is an increased prevalence of diabetes across the globe due to high levels of sugar in the blood streams and this results in numerous health issues. Diabetes reduces the quality of life, increases the risk of obesity, and early death. People with diabetes tend to be more resistant to antifungal treatment regimens due to high blood glucose levels which increases the chances of fungal growth. Consequently, diabetes patients tend to have a high risk of foot ulcerations and infections that can lead to tinea pedis or onychomycosis resulting in the need for the effective treatment of this infection.
The global Tinea Pedis Treatment market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Tinea Pedis Treatment volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Tinea Pedis Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Tinea Pedis Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Interdigital
Vesicular
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
GSK
Exeltis USA
Valeant
Incyte
Celgene
Hisamitsu Pharmaceutical
NovaBiotics
Elorac
F. Hoffmann-La Roche
Sanofi
Teva Pharmaceutical
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
